Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T92138
(Former ID: TTDC00315)
|
|||||
Target Name |
Phosphodiesterase (PDE)
|
|||||
Synonyms |
Human phosphodiesterase
Click to Show/Hide
|
|||||
Gene Name |
NO-GeName
|
|||||
Target Type |
Clinical trial target
|
[1] | ||||
Disease | [+] 2 Target-related Diseases | + | ||||
1 | Angina pectoris [ICD-11: BA40] | |||||
2 | Psoriasis [ICD-11: EA90] | |||||
Function |
Participates in processes of transmission and amplification of the visual signal. cGMP-PDEs are the effector molecules in G-protein-mediated phototransduction in vertebrate rods and cones.
Click to Show/Hide
|
|||||
BioChemical Class |
Phosphoric diester hydrolase
|
|||||
UniProt ID |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Clinical Trial Drug(s) | [+] 2 Clinical Trial Drugs | + | ||||
1 | M-518101 | Drug Info | Phase 3 | Psoriasis vulgaris | [2] | |
2 | NM-702 | Drug Info | Phase 3 | Angina pectoris | [3] | |
Discontinued Drug(s) | [+] 8 Discontinued Drugs | + | ||||
1 | Piroximone | Drug Info | Discontinued in Phase 3 | Cardiac failure | [4] | |
2 | AA-2379 | Drug Info | Discontinued in Phase 2 | Inflammation | [6] | |
3 | HN-10200 | Drug Info | Discontinued in Phase 2 | Cardiac failure | [7] | |
4 | ALBIFYLLINE | Drug Info | Discontinued in Phase 1 | Sepsis | [8] | |
5 | BBB-022 | Drug Info | Terminated | Cerebrovascular ischaemia | [9] | |
6 | Isomazole | Drug Info | Terminated | Asthma | [10] | |
7 | JTT-608 | Drug Info | Terminated | Diabetic complication | [11] | |
8 | Sch-45752 | Drug Info | Terminated | Asthma | [12] | |
Mode of Action | [+] 1 Modes of Action | + | ||||
Inhibitor | [+] 11 Inhibitor drugs | + | ||||
1 | M-518101 | Drug Info | [13] | |||
2 | NM-702 | Drug Info | [1] | |||
3 | Piroximone | Drug Info | [14] | |||
4 | AA-2379 | Drug Info | [15] | |||
5 | HN-10200 | Drug Info | [16] | |||
6 | ALBIFYLLINE | Drug Info | [17] | |||
7 | BBB-022 | Drug Info | [18] | |||
8 | Isomazole | Drug Info | [19] | |||
9 | JTT-608 | Drug Info | [20] | |||
10 | Sch-45752 | Drug Info | [21] | |||
11 | DPN-205-734 | Drug Info | [22] |
Drug Property Profile of Target | Top | |
---|---|---|
(1) Molecular Weight (mw) based Drug Clustering | (2) Octanol/Water Partition Coefficient (xlogp) based Drug Clustering | |
|
||
(3) Hydrogen Bond Donor Count (hbonddonor) based Drug Clustering | (4) Hydrogen Bond Acceptor Count (hbondacc) based Drug Clustering | |
|
||
(5) Rotatable Bond Count (rotbonds) based Drug Clustering | (6) Topological Polar Surface Area (polararea) based Drug Clustering | |
|
||
"RO5" indicates the cutoff set by lipinski's rule of five; "D123AB" colored in GREEN denotes the no violation of any cutoff in lipinski's rule of five; "D123AB" colored in PURPLE refers to the violation of only one cutoff in lipinski's rule of five; "D123AB" colored in BLACK represents the violation of more than one cutoffs in lipinski's rule of five |
Target-Related Models and Studies | Top | |||||
---|---|---|---|---|---|---|
Target Validation |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease. J Am Coll Cardiol. 2006 Dec 19;48(12):2539-45. | |||||
REF 2 | ClinicalTrials.gov (NCT01989429) Efficacy Study Comparing Topical M518101 and Vitamin D3 in Adult Psoriasis Patients. U.S. National Institutes of Health. | |||||
REF 3 | Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication. Trials. 2011; 12: 134. | |||||
REF 4 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000260) | |||||
REF 5 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000078) | |||||
REF 6 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000920) | |||||
REF 7 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001592) | |||||
REF 8 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003224) | |||||
REF 9 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009640) | |||||
REF 10 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000373) | |||||
REF 11 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011585) | |||||
REF 12 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002639) | |||||
REF 13 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
REF 14 | Circulatory effects of the PDE-inhibitors piroximone and enoximone. Br J Clin Pharmacol. 1993 Oct;36(4):309-14. | |||||
REF 15 | Inhibitory effects of methyl 7-butyl-4,5,6,7-tetrahydro-3-methylamino-4,6-dioxo-5-propyl- 2H-pyrazolo[3,4-d]pyrimidine-2-carboxylate (AA-2379) on lysosomal enzyme and arachidonic acid release from rat polymorphonuclear leukocytes and its mode of action. Agents Actions. 1989 Nov;28(3-4):248-55. | |||||
REF 16 | HN-10200 causes endothelium-independent relaxations in isolated canine arteries. Cardiovasc Drugs Ther. 1992 Apr;6(2):159-65. | |||||
REF 17 | Enhanced tumor necrosis factor suppression and cyclic adenosine monophosphate accumulation by combination of phosphodiesterase inhibitors and prostanoids. Eur J Immunol. 1995 Jan;25(1):147-53. | |||||
REF 18 | Matrix metalloproteinase inhibition prevents oxidative stress-associated blood-brain barrier disruption after transient focal cerebral ischemia. J Cereb Blood Flow Metab. 2001 Dec;21(12):1393-400. | |||||
REF 19 | Effects of isomazole on force of contraction and phosphodiesterase isoenzymes I-IV in nonfailing and failing human hearts. J Cardiovasc Pharmacol. 1991 Sep;18(3):386-97. | |||||
REF 20 | JTT-608 controls blood glucose by enhancement of glucose-stimulated insulin secretion in normal and diabetes mellitus rats. Eur J Pharmacol. 1999 Feb 12;367(1):91-9. | |||||
REF 21 | SCH 45752--an inhibitor of calmodulin-sensitive cyclic nucleotide phosphodiesterase activity. J Antibiot (Tokyo). 1993 Feb;46(2):207-13. | |||||
REF 22 | Pharmacological actions of DPN 205-734, a novel cardiotonic agent. J Cardiovasc Pharmacol. 1988 Oct;12(4):451-60. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.